Skip to content
OpenCapital
Get started

Crinetics Pharmaceuticals CRNX Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
——

Other financials

Income statement

See full
Revenue$10.7M+2,873%
Gross profit$10.5M+2,818%
Operating income-$140.4M-26.0%
Net income-$127.8M-32.1%
EPS (diluted)-$1.23-18.3%

Balance sheet

See full
Cash & equivalents$115.1M+20.1%
Total debt$47.9M-5.8%
Total equity$1.3B+2.1%
Total assets$1.4B+2.9%

Cash flow

See full
Operating cash flow-$124.7M-41.0%
CapEx$820.0K-33.8%
Free cash flow-$125.5M-40.0%

Valuation

See full
Market cap$3.79B+21.9%

Profitability

See full
Gross margin150%-15.6pp
Operating margin-3,020.3%-1,463pp
Net margin-2,747.2%-1,328pp
FCF margin-2,321.7%-1,122pp

Returns & leverage

See full
Return on equity-39.2%+14.5pp
Debt / equity0×0.0×
Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Crinetics Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
Crinetics Pharmaceuticals (CRNX) reported proceeds from sale and maturity of available for sale securities of $302.89M in Q1 2026.
How has Crinetics Pharmaceuticals's proceeds from sale and maturity of available for sale securities changed year-over-year?
Crinetics Pharmaceuticals's proceeds from sale and maturity of available for sale securities decreased by 1.2% year-over-year, from $306.48M to $302.89M.
What is the long-term trend for Crinetics Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's proceeds from sale and maturity of available for sale securities has grown at a 103.3% compound annual growth rate (CAGR), from $69.36M to $1.18B.